ArticleAssay and drug development technologies2017
Accelerating Precision Drug Development and Drug Repurposing by Leveraging Human Genetics.
Article in Assay and drug development technologies, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Identification and single-base gene-editing functional validation of a cis-EPO variant as a genetic predictor for EPO-increasing therapies.American journal of human genetics · 2022Pooled it
- Drug repurposing: a systematic review on root causes, barriers and facilitators.BMC health services research · 2022Pooled it
- Phenome-wide association studies across large population cohorts support drug target validation.Nature communications · 2018Pooled it
- Recombinant Platelet-Derived Growth Factor in Tissue Repair: A Review Exploring Frontiers in Regenerative Medicine.Plastic and reconstructive surgery · 2026Review
- Germline Variants Influence Chronic Liver Disease Progression through Distinct Pathways.medRxiv : the preprint server for health sciences · 2025Article
- Leveraging pleiotropy for the improved treatment of psychiatric disorders.Molecular psychiatry · 2025Review
- Statins for polycystic ovary syndrome in varying resource settings: a phenome-wide association study and evidence synthesis.Frontiers in pharmacology · 2025Article
- Repurposing N-acetylcysteine for management of non-acetaminophen induced acute liver failure: an evidence scan from a global health perspective.Translational gastroenterology and hepatology · 2024Article
- Artificial intelligence for chimeric antigen receptor-based therapies: a comprehensive review of current applications and future perspectives.Therapeutic advances in vaccines and immunotherapy · 2024Review
- Genetically proxied therapeutic prolyl-hydroxylase inhibition and cardiovascular risk.Human molecular genetics · 2023Article
- The grand challenge of discovering new cardiovascular drugs.Frontiers in drug discovery · 2022Article
- Precision Medicine, AI, and the Future of Personalized Health Care.Clinical and translational science · 2021Review
- Human and Machine Intelligence Together Drive Drug Repurposing in Rare Diseases.Frontiers in genetics · 2021Article
- Understanding enterprise data warehouses to support clinical and translational research.Journal of the American Medical Informatics Association : JAMIA · 2020Article
- Leveraging Human Genetics to Identify Safety Signals Prior to Drug Marketing Approval and Clinical Use.Drug safety · 2020Article
- Adhesion G protein-coupled receptors: opportunities for drug discovery.Nature reviews. Drug discovery · 2019Article
- Pharmacogenomics.Lancet (London, England) · 2019Review
- A Phenome-Wide Association Study Uncovers a Pathological Role of Coagulation Factor X duringInfection and immunity · 2019Article
- Realizing drug repositioning by adapting a recommendation system to handle the process.BMC bioinformatics · 2018Article
- Genome-wide and Phenome-wide Approaches to Understand Variable Drug Actions in Electronic Health Records.Clinical and translational science · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
The potential impact of using human genetic data linked to longitudinal electronic medical records on drug development is extraordinary; however, the practical application of these data necessitates some organizational innovations. Vanderbilt has created resources such as an easily queried database of >2.6 million de-identified electronic health records linked to BioVU, which is a DNA biobank with more than 230,000 unique samples. To ensure these data are used to maximally benefit and accelerate both de novo drug discovery and drug repurposing efforts, we created the Accelerating Drug Development and Repurposing Incubator, a multidisciplinary think tank of experts in various therapeutic areas within both basic and clinical science as well as experts in legal, business, and other operational domains. The Incubator supports a diverse pipeline of drug indication finding projects, leveraging the natural experiment of human genetics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.